Oculis Holding AG (OCS) Long-Term Deferred Tax (2023 - 2024)
Oculis Holding AG's (OCS) quarterly Long-Term Deferred Tax came in at $342456.6 in Q4 2024, up 590.39% year-on-year from $49603.6 in Q1 2024, and up 590.39% quarter-over-quarter from $49603.6 in Q4 2023.
Oculis Holding AG (OCS) Long-Term Deferred Tax (2023 - 2024) Analysis & Trends
Oculis Holding AG's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $342456.6 for Q4 2024.
- On a quarterly basis, Long-Term Deferred Tax rose 590.39% year-over-year to $342456.6 in Q4 2024; TTM through Dec 2024 was $342456.6, a 590.39% increase from a year earlier, with the FY2024 full-year figure at $341010.4, up 596.06% from the prior year.
- Long-Term Deferred Tax climbed to $342456.6 in Q4 2024 per OCS's latest filing, from $49603.6 in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $342456.6 in Q4 2024 and bottomed at $49603.6 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 342,456.55 |
| Dec 31, 2023 | 49,603.60 |